Company Profile
Equillium, Inc. Stock Price, News & Analysis
- Ticker:
- EQ
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.46 USD (-1.20%)
Close
Last updated: July 27, 2026
176M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, EQ closed down 1.20% at $2.46. No new same-company headline was identified in the current news window.
Company overview
Business overview
Equillium is a biotechnology company focused on immune-mediated diseases and inflammation. Its story centers on using immune-pathway biology to address serious autoimmune and inflammatory conditions.
Geographic Base and Sector Classification
Equillium is headquartered in the United States and listed on NASDAQ. It sits in specialty immunology biotechnology.
Business Model Characteristics
The company depends on clinical validation, translational confidence, and capital discipline while it advances a focused pipeline. Investors usually watch early data and strategic updates.
Position Within the Biotechnology Landscape
Equillium occupies a small immunology niche within biotech. It is catalyst-sensitive because the company is still proving whether its pathway biology can support a durable therapeutic thesis.
Future catalysts
Equillium’s catalysts are its immunology pipeline, especially any update that shows the cytokine-targeting strategy can still generate clinical differentiation. The company remains highly data-dependent.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 02
- 03
- 04
- 05
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTX · Source: Avalo Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Equillium, Inc. (EQ)?
Equillium, Inc. (EQ) most recently closed at 2.46 USD, a -1.20% move versus the previous session.
What is the market cap of Equillium, Inc. (EQ)?
Equillium, Inc. currently has a market capitalization of 176M USD on BioPharmSignal.
What does Equillium, Inc. do?
Equillium is a biotechnology company focused on immune-mediated diseases and inflammation. Its story centers on using immune-pathway biology to address serious autoimmune and inflammatory conditions.
On which exchange is EQ stock listed?
Equillium, Inc. (EQ) is associated with NASDAQ, United States, Biopharma.
What is Equillium?
Equillium’s catalysts are its immunology pipeline, especially any update that shows the cytokine-targeting strategy can still generate clinical differentiation.
Which conditions is Equillium, Inc. targeting with Equillium?
Equillium, Inc. is associated with immunology, inflammatory disease based on its company overview and current catalyst commentary.
How does Equillium, Inc. describe recent progress with Equillium?
Equillium’s catalysts are its immunology pipeline, especially any update that shows the cytokine-targeting strategy can still generate clinical differentiation.
What future catalysts are investors watching for Equillium, Inc.?
Equillium’s catalysts are its immunology pipeline, especially any update that shows the cytokine-targeting strategy can still generate clinical differentiation. The company remains highly data-dependent.